Benguet (OTC:BGUUF) Stock, Quote.Headers.trade-ideas

Benguet Corp is engaged in gold, nickel, and other metallic and nonmetallic mineral production, exploration, research and development, and natural resource projects. The company operates through four segments namely Mining, Health services, Logistics, and Others. The Mining segment is engaged in exploration, nickel, and gold mining operations. The Health services segment is engaged in the business of offering medical and clinical diagnostic examinations and health care services. The logistics segment is engaged in logistics services to the supply-chain requirements of various industries. The Other segments of the company is engaged in research, development, health services, and water projects.

Benguet Corp

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">Copa Holdings, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>)</h3>
<ul>
<li>Dividend Yield: 6.76%</li>
<li>Deutsche Bank analyst Michael Linenberg maintained a Buy rating and cut the price target from $145 to $130 on Aug. 8. This analyst has an accuracy rate of 75%.</li>
<li>Raymond James analyst Savanthi Syth maintained a Strong Buy rating and raised the price target from $165 to $168 on May 17. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On Sept. 11, Copa Holdings said, for Aug. 2024, capacity increased by 8.2% and system-wide passenger traffic rose by 5.8%.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1">latest CPA news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="872" height="820" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044005/image-46.png" alt="" class="wp-image-584999" style="width:726px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044005/image-46.png 872w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044005/image-46-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044005/image-46-768x722.png 768w" sizes="(max-width: 872px) 100vw, 872px" /></a></figure>
<h3 class="wp-block-heading">Karat Packaging Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul>
<li>Dividend Yield: 5.47%</li>
<li>Truist Securities analyst Jake Bartlett downgraded the stock from Buy to Hold and slashed the price target from $34 to $28 on Aug. 9. This analyst has an accuracy rate of 76%.</li>
<li>Stifel analyst Michael Hoffman reiterated a Buy rating and boosted the price target from $30 to $32 on March 15. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On Aug. 8, Karat Packaging reported worse-than-expected second-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1">latest KRT news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044049/image-47.png" alt="" class="wp-image-585001" style="width:721px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044049/image-47.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044049/image-47-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044049/image-47-768x707.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</h3>
<ul>
<li>Dividend Yield: 4.97%</li>
<li>BMO Capital analyst Fadi Chamoun maintained a Market Perform rating and cut the price target from $169 to $155 on July 24. This analyst has an accuracy rate of 80%.</li>
<li>Wells Fargo analyst Christian Wetherbee maintained an Overweight rating and slashed the price target from $156 to $134 on July 24. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Aug. 7, UPS announced its regular quarterly dividend of $1.63 per share on all outstanding Class A and Class B shares.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1">trend in UPS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044143/image-48.png" alt="" class="wp-image-585004" style="width:692px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044143/image-48.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044143/image-48-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08044143/image-48-768x709.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41221716/dow-dips-around-400-points-as-treasury-yields-top-4-investor-optimism-declines-but-fear-index-remai">Dow Dips Around 400 Points As Treasury Yields Top 4%: Investor Optimism Declines, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

News

Dividends

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Industrials Stocks Delivering High-Dividend Yields

WIIM

RBLX

Roblox shares are trading lower after Hindenburg Research issued a short report on the company.

Wells Fargo analyst Ken Gawrelski maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Underweight and raises the price target from $100 to $102.

ABNB

Wells Fargo Maintains Underweight on Airbnb, Raises Price Target to $102

Wells Fargo analyst Roger Read maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Equal-Weight and raises the price target from $100 to $110.

Wells Fargo Maintains Equal-Weight on Albemarle, Raises Price Target to $110

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

<a href="https://hindenburgresearch.com/roblox/" title="https://hindenburgresearch.com/roblox/">https://hindenburgresearch.com/roblox/</a>

Short Sellers

Watching Roblox; Hindenburg Research Issues Report Titled "Roblox: Inflated Key Metrics For Wall Street And A Pedophile Hellscape For Kids"

In his latest &#8220;Monday Markets&#8221; podcast, technical analyst CryptoCred offers insights into the current cryptocurrency market, focusing on Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) key levels and potential <a href="https://www.benzinga.com/money/bitcoin-price-prediction">trading strategies for altcoins</a>.
What Happened: CryptoCred identifies $64,200 as a crucial resistance level for Bitcoin on the weekly timeframe, noting that it represents the highest close before a recent pullback. He suggests that a breakthrough above this level could signal strength, while a rejection might lead to a deeper pullback towards $58,000-$58,700.
On Oct. 7, Bitcoin prices briefly peaked at $64,198 before dropping to $62,420 at the time of writing. 
For short to medium-term trading, CryptoCred <a href="https://www.youtube.com/watch?v=N-5ZupdUAhw">outlines</a> a range between $64,200 as the high and $58,000 as the low, with a midpoint around $61,700. He emphasizes the importance of these levels across multiple timeframes, from weekly to 4-hour charts.
Regarding altcoins, CryptoCred advises a trend-following approach with aggressive invalidation criteria. He states, &#8220;You always trail up based on the next level of support&#8230; as soon as one breaks, it&#8217;s worth getting out.&#8221; This strategy aims to avoid unnecessary drawdowns while still capturing uptrends.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41214901/bitcoins-uptober-upswing-will-resume-soon-jpmorgan">Bitcoin&#8217;s &#8216;Uptober&#8217; Upswing Will Resume Soon: JPMorgan</a>
Why It Matters: CryptoCred highlights the importance of updating invalidation levels as trends progress. He explains if traders are looking for a flat type of entry it has to be done on the low time frame. 
For trending altcoins, he suggests focusing on the nearest daily or 4-hour support levels and exiting positions if these levels break. This approach allows traders to stay in strong trends while minimizing risk when market behaviour shifts.
CryptoCred concludes by discussing the relationship between low and high timeframe trends, noting that a break in a lower timeframe trend doesn&#8217;t necessarily invalidate a higher timeframe uptrend, but may signal a potential larger pullback.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/24/10/41213262/bitcoin-ethereum-and-ai-a-conversation-with-the-ceo-of-bit-digital">Bitcoin, Ethereum, And AI: A Conversation With The CEO Of Bit Digital</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Dips Below $63K: What Does Technical Analysis Say?

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said VICI Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>) <a href="https://www.benzinga.com/quote/VICI/earnings">is &#8220;fine.&#8221;</a>
VICI Properties will release its third quarter financial results on Thursday, Oct. 31, after the close of trading on the NYSE.
Cramer said although STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) is fine, but he prefers Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>).
STMicroelectronics said it will release third-quarter earnings before the opening bell on the European Stock Exchanges on Oct. 31.
Cramer said Tetra Tech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>) is &#8220;remarkable.&#8221;
The company recently revealed that the U.S. Army Corps of Engineers (USACE), Omaha District, awarded $249 million, multiple-award contract to provide environmental assessment and design services at facilities and <a href="https://www.benzinga.com/markets/equities/24/10/41171071/tetra-tech-lands-249m-army-corps-contract-powering-eco-friendly-projects-across-us">sites throughout the United States.</a>
Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is &#8220;just ok. It's not that well-run,&#8221; Cramer said. &#8220;I would not chase the stock.&#8221;
On Sept. 26, Goldman Sachs analyst Brett Feldman maintained Crown Castle with a Neutral and raised the price target from $105 to $120.
The &#8220;Mad Money&#8221; host recommended buying Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) stock right here, adding that it is the &#8220;best of breed.&#8221;
On Oct. 1, SLB announced the joining of forces with ADNOC Drilling and Patterson-UTI to accelerate the UAE&#8217;s unconventional oil program.
&#8220;I am shocked at how low that is,&#8221; Cramer said when asked about New Fortress Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NYSE">NFE</a>). &#8220;I think that you have to stick with it.&#8221;
Last week, New Fortress Energy announced its CEO made a $50 million stock purchase.
Cramer recommended holding on to Pure Storage, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>).
On Aug. 28, Pure Storage reported quarterly earnings of 44 cents per share, which beat the analyst consensus estimate of 37 cents per share.
Price Action:
<ul>
<li>VICI Properties shares settled at $32.42 on Monday.</li>
<li>Pure Storage shares gained 0.2% to close at $51.32.</li>
<li>STMicroelectronics shares fell 0.9% to close at $28.18 during the session.</li>
<li>Crown Castle shares slipped 0.3% to close at $111.20 during Monday's session.</li>
<li>SLB shares gained 0.3% to close at $45.59 on Monday.</li>
<li>Tetra tech shares fell 0.7% to close at $48.01.</li>
<li>New Fortress Energy shares fell 6.9% to settle at $9.39 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41213879/top-3-financials-stocks-that-may-jump-this-quarter">Top 3 Financials Stocks That May Jump This Quarter</a></li>
</ul>

Long Ideas

Markets

Media

PSTG

TTEK

VICI

Jim Cramer: VICI Properties Is 'Fine', Recommends Buying This Energy Stock

Agreement with Xing Sheng Group will Bring Yoshiharu Global's Expanding Cuisine to its First International Location &nbsp;
BUENA PARK, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Yoshiharu Global Co. (NASDAQ:<a href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) ("Yoshiharu" or the "Company"), a restaurant operator specializing in authentic Japanese ramen &amp; rolls, has entered into a non-binding Memorandum of Understanding ("MoU") with Xing Sheng Group through a Master License Agreement ("MLA") for the Liaoning Province in China to introduce a new flagship Yoshiharu restaurant in Shenyang, China, home to over 43 million people.
Founded in 1991, Xing Sheng Group is a prominent Chinese conglomerate with ventures in real estate, investments, and film production, operating 17 subsidiaries in major cities across China. Its real estate arm, Shenyang Yongsheng Seven Stars Tourism Development Co. ("Shenyang Yongsheng"), specializes in developing tourist attraction centers in Shenyang and is currently constructing China's largest water park. This strategic partnership offers Yoshiharu a prime opportunity to develop a location within the water park, catering to both local residents and visiting tourists. As the capital and largest city of China's northeast Liaoning Province, Shenyang is a dynamic transportation and commercial hub of northeast China, positioning the new flagship location to serve the ethnically and culturally diverse population.
Following Yoshiharu's recent expansion into Las Vegas, this flagship location in Shenyang will play a pivotal role in advancing the Company's growth strategy by introducing and expanding the Yoshiharu brand and its culinary offerings to new markets.

Global

YOSH

Yoshiharu Announces Strategic Partnership With Xing Sheng Group To Bring Yoshiharu Global's Expanding Cuisine To Its First International Location

Initial Development Order with New Customer Follows Recently Granted European Defense Manufacturing License
ORLANDO, Fla., Oct. 8, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4272471-1&amp;h=3777019525&amp;u=https%3A%2F%2Fwww.lightpath.com%2F&amp;a=LightPath+Technologies%2C+Inc.">LightPath Technologies, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTH#NASDAQ">LPTH</a>) ("LightPath," the "Company," or "we"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced receipt of an initial development contract from a new European defense customer for the use of BlackDiamond glass in optical systems.
The BlackDiamond glass, which has already completed qualification with the customer, utilizes the Company's proprietary BlackDiamond&#x2122; Chalcogenide material,&nbsp; and will be utilized in the prototypes within the defense customer's optical systems. Upon successful development into the customer's next-generation optical systems, LightPath maintains the opportunity for larger recurring orders in the future.

Contracts

LPTH

LightPath Technologies Announced Receipt Of An Initial Development Contract From A New European Defense Customer For The Use Of BlackDiamond Glass In Optical Systems

Redburn Atlantic analyst Qize Ding initiates coverage on Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy rating and announces Price Target of $86.

Initiation

LEGN

Redburn Atlantic Initiates Coverage On Legend Biotech with Buy Rating, Announces Price Target of $86

Highlights Seanergy's Value Creating Strategy &nbsp;
Underscores Strength of Highly Qualified Seanergy Board of Directors Overseeing Strategy
Encourages Shareholders to Vote the WHITE Proxy Card "FOR" Seanergy's Director Nominees and "AGAINST" Economou's Proposals
ATHENS, Greece, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Seanergy Maritime Holdings Corp. ("Seanergy" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) today announced that it has mailed a letter from Stamatis Tsantanis, Seanergy's Chairman and Chief Executive Officer, to shareholders in connection with the Company's upcoming 2024 Annual Meeting of Shareholders.
The letter highlights the Company's:
<ul>
<li>Transformation over the last four years into a prominent pure-play Capesize shipping company with attractive competitive positioning and an improved balance sheet, poised to capitalize on tailwinds in the Capesize market; &nbsp;</li>
<li>Comprehensive strategic plan that has enabled Seanergy to grow its business, deliver record financial results and increase returns to shareholders; and 
<ul>
<li>Highly qualified directors who each brings a deep understanding of the industry. Their continued oversight is critical for us to build on our momentum and execute our strategic plans.</li>
</ul>
</li>
</ul>

Management

SHIP

Seanergy Maritime Mails CEO Letter To Shareholders; Highlights Seanergy's Value Creating Strategy; Underscores Strength Of Highly Qualified Seanergy Board Of Directors Overseeing Strategy

ECD Automotive Design, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) ("ECD" or the "Company"), an industry leader in building and selling restored, modified and electrified Land Rover Defenders, Jaguar E-Types, Ford Mustangs, and Toyota FJs announced today it has embarked upon a new retail strategy to own and operate brick and mortar showrooms to market and sell ECD's vehicles. In support of the strategy, ECD has signed an agreement with Site Selection Group, of Dallas, Texas, to research and identify real estate locations to effectuate ECD's retail showroom concept.

ECDA

ECD Automotive Design Has Embarked Upon A New Retail Strategy To Own And Operate Brick And Mortar Showrooms To Market And Sell ECD's Vehicles

<a href="https://www.globenewswire.com/Tracker?data=vARWDows7IJhE1naXPMjDff3-1ECuR39AP9d5fjFZBDgViDwbctWKjUL5Xq6oSsYxfpv5r_OLtqFTXtTnSN_7q1F8Ot34ej6Hn8VOfp_A44EyOO7Fhe58xwnoI5sJGyt">SeaStar Medical Holding Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the activation of Brooke Army Medical Center (BAMC) and the United States Army Institute of Surgical Research (USAISR), expanding the number of sites in its NEUTRALIZE-AKI pivotal trial. This trial is evaluating the safety and efficacy of SeaStar Medical's innovative Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI) in adult ICU patients receiving continuous kidney replacement therapy (CKRT). With the inclusion of these prestigious military medical facilities, SeaStar Medical now has 11 active clinical sites with 48 subjects enrolled to date. &nbsp;
The SCD has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for adults with AKI, which is awarded to the SCD as a therapy to treat a serious or life-threatening condition with preliminary clinical evidence indicating it may demonstrate substantial improvement over available therapies on clinically significant endpoints. In July 2024, the U.S. Centers for Medicare and Medicaid (CMS) granted Category B coverage for certain expenses incurred by medical centers treating Medicare and Medicaid patients enrolled in the NEUTRALIZE-AKI pivotal trial.

Biotech

General

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities, Brooke Army Medical Center And The United States Army Institute Of Surgical Research

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/10/07/final-trades-diamondback-energy-owens-corning-synovus-and-the-xlf.html">Halftime Report Final Trades</a>,&#8221; Anastasia Amoroso of iCapital named The Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>), saying the financial sector is set to report earnings at the end of the week. Although this quarter is not going to be great, but she believes it will be <a href="https://www.benzinga.com/quote/XLF">better going forward</a>.
Bill Baruch of Blue Line Capital named Owens Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) as his final trade.
On Oct. 7, Wells Fargo analyst Sam Reid maintained Owens-Corning with an Equal-Weight and raised the price target from $165 to $175.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Brian Belski of BMO Capital said Synovus Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) has a 3.5% dividend yield.
Synovus Financial will announce third quarter earnings results after the closing bell on Wednesday, Oct. 16. Analysts expect the company to report quarterly earnings at $1.08 per share, up from 84 cents per share in the year-ago period. The company projects to report quarterly revenue of $559.44 million.
Joseph&nbsp;M.&nbsp;Terranova of Virtus Investment Partners picked Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), an energy name, amid a surge in oil prices.
On Oct. 4, BMO Capital analyst Phillip Jungwirth upgraded Diamondback Energy from Market Perform to Outperform and raised the price target from $205 to $215.
Price Action:
<ul>
<li>Owens Corning shares gained 5.5% to close at $181.42 during Monday's session.</li>
<li>The Financial Select Sector SPDR Fund fell 1.2% on Monday.</li>
<li>Synovus Financial shares fell 1.1% to close at $43.34 during Monday's session.</li>
<li>Diamondback Energy shares gained 2.5% to settle at $199.50 on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41213879/top-3-financials-stocks-that-may-jump-this-quarter">Top 3 Financials Stocks That May Jump This Quarter</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

FANG

Owens Corning, Synovus Financial, Diamondback Energy And More On CNBC's 'Final Trades'

Wells Fargo analyst Roger Read maintains Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) with a Overweight and raises the price target from $84 to $88.

SHEL

Wells Fargo Maintains Overweight on Shell, Raises Price Target to $88

Personalized healthcare company Accolade Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) stock is trading slightly higher after the company announced&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41224447/accolade-announces-results-for-fiscal-second-quarter-2025" rel="noreferrer noopener">fiscal second quarter 2025 results</a>.
The company reported a revenue increase of 10% to $106.36 million, beating the consensus of $105.01 million. Loss per share of $0.30 beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus loss of $0.44</a>.
Adjusted gross profit rose 17% Y/Y to $50.30 million. Adjusted EBITDA loss narrowed to $2.83 million from $8.76 million a year ago.
As of August 31, ACCD&#8217;s cash and cash equivalents stood at $234.35 million.&nbsp;
&#8220;As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow,&#8221; said Rajeev Singh, Accolade Chair and CEO.
Outlook: Accolade expects third-quarter revenues of $104 million—$107 million (versus the $110.16 million estimate) and&nbsp;an adjusted EBITDA loss of $3 million—$5 million.
The company <a target="_blank" href="https://www.benzinga.com/news/earnings/24/06/39536835/accolade-stock-tumbles-on-q1-earnings-weak-guidance-what-you-need-to-know" rel="noreferrer noopener">reiterated fiscal 2025</a> revenues of $460 million—$475 million versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $466.97 million</a> and adjusted EBITDA of $15 million—$20 million.
Accolade stock plunged over 67% year-to-date as the analysts cut their price targets on the stock during the <a target="_blank" href="https://www.benzinga.com/quote/ACCD/analyst-ratings" rel="noreferrer noopener">last two quarterly prints</a>.
Price Action: ACCD stock is up 0.25% at $3.98 premarket at the last check Tuesday.

Earnings

Equities

Guidance

ACCD

Accolade's Q2 Boost: Revenue Rises, Losses Shrink, And Profitability Looms

First purchase order under agreement is for 20 Scorpion units
LAS VEGAS, Oct. 08, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Xwsu3KPpo2lGKpFkp8nOLeVluDrP1FqmOLl2KoJvGKXeBl20iEsNrR5Ves86StxgJ1NDxOe4MoiYRO1LZLS6b0J9-JSKLQabc2s9agjQq0o=">Richtech Robotics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) ("Richtech Robotics"), a Nevada-based provider of AI-driven service robots, today announces it has signed a distribution agreement with Sproutmation, LLC ("Sproutmation"), a commercial robotics and automation solutions delivery provider. Sproutmation's first purchase order is for 20 Scorpion units. Under the arrangement, Sproutmation has agreed to an annual sales target of 100 robot units.
"We are continuously expanding our ecosystem of distribution partners and are pleased to announce our agreement with Sproutmation," said Matt Casella, President of Richtech Robotics. "Our solutions are synergistic with Sproutmation's offerings as the company is focused on robots that provide automation for clients. This collaboration will allow us to reach even more organizations across the country."

Richtech Robotics Signs Distribution Agreement With Sproutmation, LLC, Commercial Robotics And Automation Solutions Delivery Provider; First Purchase Order Under Agreement Is For 20 Scorpion Units

GeneDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for more than 14,000 infants through its participation in groundbreaking research studies which aim to explore the clinical utility and implementation of utilizing genome sequencing to expand standard newborn screening (NBS). Through these studies, GeneDx has conducted more gNBS than any other lab and gained experience understanding diverse multi-site implementation strategies, positioning GeneDx as a laboratory leader set to revolutionize the standard approach to NBS.
Early diagnosis is critical to ensuring patients have the best chance at fighting the progression of disease. The broad availability of gNBS can significantly decrease time-to-diagnosis, which is particularly critical for diagnoses with actionable outcomes, including associated treatments and/or interventions. Through a retrospective analysis of its large database - currently more than 700,000 exomes and genomes - GeneDx looked to identify positive findings that would have been reported at birth had gNBS been available to patients as newborns. This analysis showed that greater than 21% of patients would have received a diagnosis earlier, on average by more than 8 years.
As the lab behind industry moving research studies, including GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns), which has served more than 10,000 infants, and its early involvement in Early Check, supporting 2,000 infants, GeneDx has a unique understanding of the complexities of offering gNBS at scale. Interpretation of gNBS is heavily dependent on having a robust and diverse database of clinically significant variants to reduce the burden of analysis. Additionally, expertise in technical evaluation and understanding sequencing data outputs are necessary to inform variant interpretation and deliver a more definitive diagnosis.

GeneDx Data To Be Presented At The International Conference On Newborn Sequencing Highlighting Lessons Learned From The Guardian And Early Check Newborn Sequencing Studies Showcasing GeneDx's Deep Expertise As The Leader For gNBS

Wells Fargo analyst Vik Chopra initiates coverage on Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) with a Equal-Weight rating and announces Price Target of $20.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Benguet

Benguet (BGUUF) Forecast

Benguet (OTC:BGUUF) Stock, Quote.Headers.trade-ideas